Mark A. Velleca G1 Therapeutics, Inc. (GTHX) insider trading activity

Mark A. Velleca is of G1 Therapeutics, Inc.. Currently has a direct ownership of 116,000 shares of GTHX, which is worth approximately $829,400. The most recent transaction as insider was on May 12, 2021, when has been sold 10,000 shares (Common Stock) at a price of $20.07 per share, resulting in proceeds of $200,700. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 116K

0% 3M change

0% 12M change

Total Value Held $829,400

Mark A. Velleca Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 12 2021	SELL Open market or private sale	$200,700 $20.07 p/Share	10,000 Reduced 19.61%	41,000 Common Stock
May 12 2021	BUY Exercise of conversion of derivative security	$3,900 $0.39 p/Share	10,000 Added 16.39%	51,000 Common Stock
May 11 2021	SELL Open market or private sale	$191,000 $19.1 p/Share	10,000 Reduced 19.61%	41,000 Common Stock
May 11 2021	BUY Exercise of conversion of derivative security	$3,900 $0.39 p/Share	10,000 Added 16.39%	51,000 Common Stock
Apr 15 2021	SELL Open market or private sale	$249,600 $24.96 p/Share	10,000 Reduced 19.61%	41,000 Common Stock
Apr 15 2021	BUY Exercise of conversion of derivative security	$3,900 $0.39 p/Share	10,000 Added 16.39%	51,000 Common Stock
Apr 14 2021	SELL Open market or private sale	$245,300 $24.53 p/Share	10,000 Reduced 19.61%	41,000 Common Stock
Apr 14 2021	BUY Exercise of conversion of derivative security	$3,900 $0.39 p/Share	10,000 Added 16.39%	51,000 Common Stock
Apr 13 2021	SELL Open market or private sale	$238,900 $23.89 p/Share	10,000 Reduced 19.61%	41,000 Common Stock
Apr 13 2021	BUY Exercise of conversion of derivative security	$3,900 $0.39 p/Share	10,000 Added 16.39%	51,000 Common Stock
Feb 18 2021	SELL Open market or private sale	$260,200 $26.02 p/Share	10,000 Reduced 19.61%	41,000 Common Stock
Feb 18 2021	BUY Exercise of conversion of derivative security	$37,200 $3.72 p/Share	10,000 Added 16.39%	51,000 Common Stock
Feb 17 2021	SELL Open market or private sale	$280,000 $28.0 p/Share	10,000 Reduced 19.61%	41,000 Common Stock
Feb 17 2021	BUY Exercise of conversion of derivative security	$37,200 $3.72 p/Share	10,000 Added 16.39%	51,000 Common Stock
Feb 16 2021	SELL Open market or private sale	$397,771 $36.03 p/Share	11,040 Reduced 21.21%	41,000 Common Stock
Feb 16 2021	BUY Exercise of conversion of derivative security	$41,069 $3.72 p/Share	11,040 Added 17.5%	52,040 Common Stock
Jan 21 2021	SELL Open market or private sale	$206,400 $20.64 p/Share	10,000 Reduced 19.61%	41,000 Common Stock
Jan 21 2021	BUY Exercise of conversion of derivative security	$37,200 $3.72 p/Share	10,000 Added 16.39%	51,000 Common Stock
Jan 20 2021	SELL Open market or private sale	$215,100 $21.51 p/Share	10,000 Reduced 21.28%	37,000 Common Stock
Jan 20 2021	BUY Exercise of conversion of derivative security	$28,840 $2.06 p/Share	14,000 Added 25.45%	41,000 Common Stock
Jan 19 2021	SELL Open market or private sale	$208,800 $20.88 p/Share	10,000 Reduced 21.28%	37,000 Common Stock
Jan 19 2021	BUY Exercise of conversion of derivative security	$37,200 $3.72 p/Share	10,000 Added 17.54%	47,000 Common Stock
Dec 17 2020	SELL Open market or private sale	$199,700 $19.97 p/Share	10,000 Reduced 21.28%	37,000 Common Stock
Dec 17 2020	BUY Exercise of conversion of derivative security	$37,200 $3.72 p/Share	10,000 Added 17.54%	47,000 Common Stock
Dec 16 2020	SELL Open market or private sale	$192,000 $19.2 p/Share	10,000 Reduced 21.28%	37,000 Common Stock

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

PRESIDENT & CEO

MAV

Mark A. Velleca

Research Triangle Park, NC

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GTHX shares.

Notify only if

Value

Insider Trading

Get notified when an G1 Therapeutics, Inc. insider buys or sells GTHX shares.

Notify only if

Operation

Value

Type

News

Receive news related to G1 Therapeutics, Inc.

Track Activities on GTHX

Account